PMID- 38201619
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240114
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 16
IP  - 1
DP  - 2023 Dec 30
TI  - A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two 
      High-Specialized Centers in Italy: Effectiveness and Safety.
LID - 10.3390/cancers16010192 [doi]
LID - 192
AB  - BACKGROUND: Uterine leiomyosarcoma (uLMS) is characterized by aggressive behavior 
      associated with a high risk of relapse and mortality. Several therapeutic agents 
      have been employed in the treatment of metastatic disease, with a poor objective 
      response rate. Pazopanib, approved in 2012, is a multi-targeted, orally active 
      small molecule that exerts its effects by inhibiting several tyrosine kinases. To 
      date, poor research on real-life data has been conducted. We aimed to assess the 
      effectiveness and safety of the drug in everyday clinical practice. METHODS: We 
      present results of multicenter retrospective data on 38 patients with heavily 
      pretreated metastatic uLMS who underwent oral pazopanib during their therapeutic 
      journey. RESULTS: At a median follow-up of 8.6 months, the disease control rate 
      was 55.2%, with 17% partial responses and 15 patients (39.5%) with stable 
      disease. At a median follow-up of 8.6 months, median progression-free survival 
      was 4 months, and median overall survival was 19.8 months. The most common grade 
      3 adverse events (AEs) drug-related were hepatic toxicities, diarrhea, 
      hypertension, nausea, and vomiting (all of them with an incidence of 5% 
      considering the whole study cohort). No grade 4 AEs occurred. CONCLUSIONS: 
      Pazopanib in everyday clinical practice is safe and shows a good disease control 
      rate with prolonged survival.
FAU - Mantiero, Mara
AU  - Mantiero M
AUID- ORCID: 0000-0002-1016-4995
AD  - Department of Gynecologic Oncology, National Cancer Institute of Milan, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Bini, Marta
AU  - Bini M
AD  - Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 
      1, 20133 Milan, Italy.
FAU - Polignano, Maggie
AU  - Polignano M
AD  - Department of Gynecologic Oncology, National Cancer Institute of Milan, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Porcu, Luca
AU  - Porcu L
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing 
      Centre, Robinson Way, Cambridge CB2 0RE, UK.
FAU - Sanfilippo, Roberta
AU  - Sanfilippo R
AD  - Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 
      1, 20133 Milan, Italy.
FAU - Fabbroni, Chiara
AU  - Fabbroni C
AD  - Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 
      1, 20133 Milan, Italy.
FAU - Parma, Gabriella
AU  - Parma G
AD  - Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe 
      Ripamonti, 435, 20141 Milan, Italy.
FAU - Lapresa, Mariateresa
AU  - Lapresa M
AD  - Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe 
      Ripamonti, 435, 20141 Milan, Italy.
FAU - Calidona, Carmelo
AU  - Calidona C
AD  - Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe 
      Ripamonti, 435, 20141 Milan, Italy.
AD  - Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, 
      Piazzale Aristide Stefani 1, 37126 Verona, Italy.
FAU - Silvestri, Cecilia
AU  - Silvestri C
AD  - Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 
      1, 20133 Milan, Italy.
FAU - Franza, Andrea
AU  - Franza A
AD  - Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 
      1, 20133 Milan, Italy.
FAU - Raspagliesi, Francesco
AU  - Raspagliesi F
AD  - Department of Gynecologic Oncology, National Cancer Institute of Milan, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Colombo, Nicoletta
AU  - Colombo N
AD  - Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe 
      Ripamonti, 435, 20141 Milan, Italy.
AD  - University of Milan-Bicocca, Piazza dell'Ateneo Nuovo 1, 20126 Milan, Italy.
FAU - Ducceschi, Monika
AU  - Ducceschi M
AD  - Department of Gynecologic Oncology, National Cancer Institute of Milan, Via 
      Venezian 1, 20133 Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20231230
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10777896
OTO - NOTNLM
OT  - effectiveness
OT  - pazopanib
OT  - safety
OT  - survival
OT  - uterine leyomiosarcoma
COIS- The authors declare no conflict of interest.
EDAT- 2024/01/11 07:42
MHDA- 2024/01/11 07:43
PMCR- 2023/12/30
CRDT- 2024/01/11 01:06
PHST- 2023/11/22 00:00 [received]
PHST- 2023/12/20 00:00 [revised]
PHST- 2023/12/25 00:00 [accepted]
PHST- 2024/01/11 07:43 [medline]
PHST- 2024/01/11 07:42 [pubmed]
PHST- 2024/01/11 01:06 [entrez]
PHST- 2023/12/30 00:00 [pmc-release]
AID - cancers16010192 [pii]
AID - cancers-16-00192 [pii]
AID - 10.3390/cancers16010192 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Dec 30;16(1):192. doi: 10.3390/cancers16010192.